Skip to main content

Advertisement

Table 2 Longitudinal analysis of allergic disease symptoms with sensitization at 1, 3 and 6 years of age

From: Prenatal omega-3 LCPUFA and symptoms of allergic disease and sensitization throughout early childhood – a longitudinal analysis of long-term follow-up of a randomized controlled trial

Outcome Year ω-3 LCPUFAa
n (%)
Controla
n (%)
RR (95% CI) P-value Interaction
p-value
Adjusted RRb
(95% CI)
Adjusted
p-value
Interaction p-valueb
Any allergic disease symptoms with sensitization 1 15/363 (4.13%) 22/330 (6.67%) 0.62 (0.33, 1.17) 0.14 0.51 0.63 (0.33, 1.19) 0.16 0.49
3 58/313 (18.53%) 61/291 (20.96%) 0.88 (0.64, 1.22) 0.45   0.89 (0.65, 1.23) 0.48  
6 76/280 (27.14%) 82/263 (31.18%) 0.87 (0.67, 1.13) 0.30   0.92 (0.71, 1.19) 0.54  
All years    0.85 (0.66, 1.08) 0.18   0.88 (0.69, 1.12) 0.29  
Rhinitis symptoms with sensitization 3 25/327 (7.65%) 28/301 (9.30%) 0.82 (0.49, 1.38) 0.46 0.90 0.83 (0.50, 1.39) 0.48 0.87
6 55/298 (18.46%) 60/276 (21.74%) 0.85 (0.61, 1.18) 0.33   0.87 (0.63, 1.20) 0.39  
All years    0.84 (0.62, 1.14) 0.27   0.86 (0.63, 1.16) 0.32  
Rhino-conjunctivitis symptoms with sensitization 3 12/331 (3.63%) 20/304 (6.58%) 0.55 (0.27, 1.11) 0.09 0.16 0.55 (0.28, 1.11) 0.09 0.16
6 34/304 (11.18%) 33/281 (11.74%) 0.95 (0.61, 1.49) 0.83   0.96 (0.61, 1.51) 0.87  
All years    0.81 (0.54, 1.21) 0.30   0.81 (0.55, 1.21) 0.31  
Wheeze symptoms with sensitization 1 16/357 (4.48%) 29/329 (8.81%) 0.51 (0.28, 0.92) 0.03 0.13 0.52 (0.29, 0.94) 0.03 0.13
3 36/317 (11.36%) 35/295 (11.86%) 0.96 (0.62, 1.48) 0.84   0.96 (0.63, 1.49) 0.87  
6 38/290 (13.10%) 38/276 (13.77%) 0.95 (0.63, 1.45) 0.82   0.99 (0.65, 1.51) 0.97  
All years    0.83 (0.60, 1.15) 0.26   0.85 (0.62, 1.17) 0.33  
Eczema symptoms with sensitization 1 15/363 (4.13%) 22/330 (6.67%) 0.62 (0.33, 1.17) 0.14 0.68 0.63 (0.34, 1.18) 0.15 0.64
3 34/324 (10.49%) 41/301 (13.62%) 0.77 (0.50, 1.18) 0.23   0.78 (0.51, 1.19) 0.25  
6 24/303 (7.92%) 26/277 (9.39%) 0.84 (0.50, 1.43) 0.53   0.88 (0.52, 1.50) 0.65  
All years    0.76 (0.52, 1.11) 0.15   0.77 (0.53, 1.13) 0.19  
  1. For ω-3 LCPUFA and control groups, data are number of subjects (percentage)
  2. Rhinitis & Rhino-conjunctivitis symptoms not assessed at 1 year
  3. Abbreviations: CI confidence interval, ω-3 LCPUFA long chain polyunsaturated fatty acid, RR relative risk
  4. a bAdjusted for enrolling centre, parity, child sex and maternal history of allergic disease